Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines.

MLA

Węgierek-Ciura, Katarzyna, et al. “Inhibition of MC38 Colon Cancer Growth by Multicomponent Chemoimmunotherapy with Anti-IL-10R Antibodies, HES-MTX Nanoconjugate, Depends on Application of IL-12, IL-15 or IL-18 Secreting Dendritic Cell Vaccines.” Frontiers in Immunology, Aug. 2023, pp. 1–21. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1212606.

APA

Węgierek-Ciura, K., Mierzejewska, J., Szczygieł, A., Rossowska, J., Wróblewska, A., Świtalska, M., Goszczyński, T. M., Szermer-Olearnik, B., & Pajtasz-Piasecka, E. (2023). Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines. Frontiers in Immunology, 1–21. https://doi.org/10.3389/fimmu.2023.1212606

Chicago

Węgierek-Ciura, Katarzyna, Jagoda Mierzejewska, Agnieszka Szczygieł, Joanna Rossowska, Anna Wróblewska, Marta Świtalska, Tomasz M. Goszczyński, Bożena Szermer-Olearnik, and Elżbieta Pajtasz-Piasecka. 2023. “Inhibition of MC38 Colon Cancer Growth by Multicomponent Chemoimmunotherapy with Anti-IL-10R Antibodies, HES-MTX Nanoconjugate, Depends on Application of IL-12, IL-15 or IL-18 Secreting Dendritic Cell Vaccines.” Frontiers in Immunology, August, 1–21. doi:10.3389/fimmu.2023.1212606.